2 ASX biotech shares Bell Potter just upgraded to buy

These biotech shares could be high risk/high reward options.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have a high tolerance for risk, then read on! That's because Bell Potter has just upgraded two ASX biotech shares to buy ratings this morning.

Here's why the broker is feeling upbeat about these high-risk stocks:

Genetic Signatures Ltd (ASX: GSS)

According to the note, the broker has upgraded this global molecular diagnostics company's shares to a speculative buy rating with a trimmed price target of 90 cents. This implies a 78% upside from current levels.

Bell Potter sees a number of catalysts on the horizon which it feels could give the ASX biotech share a major boost. The broker explains:

We upgrade our recommendation to Buy (Speculative) with valuation of $0.90. The key potential catalysts are FDA 510(k) clearance for the Gastrointestinal Parasite kit, US commercial launch, completion of Respiratory kit clinical trial and broader engagement within the domestic and European market.

Mesoblast Ltd (ASX: MSB)

Bell Potter has also upgraded this ASX biotech share to a speculative buy rating with a 58 cents price target. This suggests a potential upside of 57% for investors.

While the broker was disappointed with the company's FDA blow last month, it highlights that early paediatric approval for remestemcel-L in GvHD remains an option for the allogeneic cellular medicines developer.

Subject to successfully generating new data, the broker estimates the company could resubmit the Biological License Application in the first quarter of 2024 followed by a two-month review period from the US FDA.

However, the real driver of its upgrade was Mesoblast's valuation. It explains:

There are no changes to earnings and valuation remains unchanged at $0.58. We upgrade to Buy (Speculative) based on share price movement. The announcements discussed here are encouraging for a potential approval in FY24, however, markets are likely to remain unconvinced until the FDA provides an approval.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Person with a handful of Australian dollar notes, symbolising dividends.
Dividend Investing

Which ASX 200 healthcare share will pay the best dividend yield in FY24?

Healthcare stocks are a traditional defensive play in challenging economic times.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

Can NIB shares reach $9 by Christmas?

It has been a good few weeks for shareholders. Can the stock keep going?

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Broker Notes

CSL shares up 15% in 5 weeks amid two hedge funds placing opposing bets

Let's see what these funds have to say about CSL shares.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Why is the Mesoblast share price sinking 25% on Tuesday?

This biotech is being sold off today. But why?

Read more »

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Healthcare Shares

Why is the Mesoblast share price in a trading halt?

Is Mesoblast raising funds again? Let's find out.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »